{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:50:27Z","timestamp":1769075427565,"version":"3.49.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the effectiveness of tacrolimus in patients with noninfectious intermediate, posterior, or panuveitis needing a two-immunosuppressive-agent regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Design: Retrospective cohort study. Setting: Two tertiary-care uveitis practices at academic medical centers. Patient population: Thirty-two patients with noninfectious intermediate, posterior, or panuveitides in whom single-agent immunosuppression was inadequate to effect successful corticosteroid sparing. Intervention: tacrolimus, added as the second immunosuppressive agent. Main outcome measure: successful corticosteroid sparing, defined as inactive uveitis at a dose of prednisone \u22647.5 mg\/day.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Active uveitis was present in 65.6% of patients at initiation of tacrolimus, and the median time to inactive uveitis was 1.5 months (95% confidence interval 1.2, 4.08). The median time to successful corticosteroid sparing was 3.9 months (95% confidence interval 1.41, 6.67), and by 6 months of follow-up successful corticosteroid sparing was achieved in 75% of patients. Tacrolimus was discontinued for side effects in five patients, three for tremor, and two for hyperglycemia. All side effects were reversible with tacrolimus discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Tacrolimus seems to have efficacy as a second immunosuppressive agent in two-immunosuppressive drug regimens, when a single agent does not permit successful corticosteroid sparing. Side effects were reversible with tacrolimus discontinuation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003836","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:27:35Z","timestamp":1684164455000},"page":"1480-1486","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["TACROLIMUS FOR IMMUNOSUPPRESSION IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE, POSTERIOR, OR PANUVEITIDES"],"prefix":"10.1097","volume":"43","author":[{"given":"Douglas A.","family":"Jabs","sequence":"first","affiliation":[{"name":"Department of Epidemiology, the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;"},{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;"},{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl S.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"},{"name":"Department of Ophthalmology, the New York Eye and Ear Infirmary of Mount Sinai, the Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karishma A.","family":"Habbu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan K.","family":"Berkenstock","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryn M.","family":"Burkholder","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Chaon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the Wilmer Eye Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avnish","family":"Deobhakta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, the New York Eye and Ear Infirmary of Mount Sinai, the Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09273940490883671","article-title":"Treatment of ocular inflammation","volume":"12","author":"Jabs","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","year":"2011","journal-title":"Ophthalmology"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","year":"2017","journal-title":"J Am Med Assoc"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis: glucocorticoid dose thresholds and increased mortality rates in RA","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/epirev\/mxac001","article-title":"The conundrum of clinical trials for the uveitides: appropriate outcome measures for one treatment used in several diseases","volume":"44","author":"Jabs","year":"2022","journal-title":"Epidemiologic Rev"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ajo.2014.08.039","article-title":"Success with single agent immunosuppression for multifocal choroidopathies","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1080\/09273948.2021.1930063","article-title":"Efficacy of tacrolimus in uveitis, and the usefulness of serum tacrolimus levels in predicting disease control. results from a single large center","volume":"30","author":"Luis","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2007.08.039","article-title":"Loss of visual field among patients with birdshot chorioretinopathy","volume":"145","author":"Thorne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2021.03.054","article-title":"Classification criteria for intermediate uveitis, non-pars planitis type","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification criteria for sarcoidosis-associated uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2021.03.059","article-title":"Classification criteria for birdshot chorioretinitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2021.03.043","article-title":"Classification criteria for multifocal choroiditis with panuveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ajo.2021.03.038","article-title":"Classification criteria for serpiginous choroiditis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","article-title":"Classification criteria for Beh\u00e7et disease uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","article-title":"Classification criteria for Vogt-Koyanagi-Harada disease","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.transproceed.2009.01.116","article-title":"Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers","volume":"41","author":"Marchewka","year":"2009","journal-title":"Transplant Proc"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2215\/CJN.03850510","article-title":"Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients","volume":"6","author":"Fioretto","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-20250605","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for non-infectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"R31-20250605","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate vs. methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"key":"R32-20250605","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamaophthalmol.2019.3964","article-title":"Antimetabolite therapy for uveitis, methotrexate or mycophenolate?","volume":"137","author":"Jabs","year":"2019","journal-title":"JAMA Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:08:28Z","timestamp":1749143308000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003836","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}